Shoal Point Energy Aktie [WKN DE: A1H60T / ISIN: CA82489D1096]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Shoal Point Energy Ltd.

22.06.17		Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease (PR Newswire)
22.06.17		Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease (PR Newswire)
21.06.17		Shire plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts of a Single-Entity Amphetamine Product) - A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older (PR Newswire)
25.05.17		Shire to Participate at the Jefferies Healthcare Conference (PR Newswire)
19.05.17		Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology (PR Newswire)
19.05.17		Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology (PR Newswire)
18.05.17		The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis (PR Newswire)
18.05.17		The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis (PR Newswire)
18.05.17		Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial (PR Newswire)
18.05.17		Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial (PR Newswire)
16.05.17		Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association (PR Newswire)
02.05.17		Shire Delivers Strong Q1 2017 Revenue Growth While Advancing Late-stage Pipeline (PR Newswire)
02.05.17		Shire Delivers Strong Q1 2017 Revenue Growth While Advancing Late-stage Pipeline (PR Newswire)
01.05.17		Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications (PR Newswire)
01.05.17		Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications (PR Newswire)
26.04.17		Shire Granted EU Conditional Marketing Authorisation for Natpar[®▼] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism (PR Newswire)
26.04.17		Shire Granted EU Conditional Marketing Authorisation for Natpar[®▼] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism (PR Newswire)
25.04.17		Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference (PR Newswire)
25.04.17		Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference (PR Newswire)
24.04.17		Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI) (PR Newswire)
24.04.17		Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI) (PR Newswire)
17.04.17		Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide (PR Newswire)
17.04.17		Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide (PR Newswire)
30.03.17		INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan (PR Newswire)
30.03.17		INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan (PR Newswire)
22.03.17		Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura (PR Newswire)
16.03.17		Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor [human]) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE (PR Newswire)
16.03.17		Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor [human]) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE (PR Newswire)
06.03.17		CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients' Previous Immunoglobulin Therapy (PR Newswire)
01.03.17		Shire to Participate at the Cowen 37th Annual Healthcare Conference (PR Newswire)
01.03.17		Shire to Participate at the Cowen 37th Annual Healthcare Conference (PR Newswire)
24.02.17		CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism (PR Newswire)
24.02.17		CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism (PR Newswire)
23.02.17		New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease (PR Newswire)
23.02.17		New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease (PR Newswire)
23.02.17		Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases (PR Newswire)
23.02.17		Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases (PR Newswire)
16.02.17		Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline (PR Newswire)
16.02.17		Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline (PR Newswire)
14.02.17		Shire to Highlight Advancements in Rare Genetic Diseases (PR Newswire)
07.02.17		Shire Responds to U.S. Federal Trade Commission Civil Action (PR Newswire)
07.02.17		Shire Responds to U.S. Federal Trade Commission Civil Action (PR Newswire)
01.02.17		New Data From Shire Aim to Help Close the Diagnosis and Treatment Gap for People With Hemophilia (PR Newswire)
01.02.17		New Data From Shire Aim To Help Close the Diagnosis and Treatment Gap for People With Hemophilia (PR Newswire)
19.01.17		U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD (PR Newswire)
19.01.17		U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD (PR Newswire)
27.12.16		Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings (PR Newswire)
27.12.16		Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings (PR Newswire)
02.12.16		Shire Reports on Four Decades of Real-World Safety Experience With FEIBA® [Anti-Inhibitor Coagulant Complex] (PR Newswire)
02.12.16		Shire Reports on Four Decades of Real-World Safety Experience With FEIBA® [Anti-Inhibitor Coagulant Complex] (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: Jetzt einsteigen und Millionär werden?

Insolvente KTM hat Dezember-Löhne überwiesen - Pierer Mobility-Aktie legt zweistellig zu

Bitcoin-Kurs stabilisiert sich nach Rückgang vom Vortag

Crash oder Rally: Das sind die Experten-Prognosen für Kryptowährungen wie Bitcoin, Ethereum & Co. im Jahr 2025

Pierer Mobility-Aktie mit zweistelligem Kurssprung: KTM AG wird fortgeführt - Eigenverwaltung bleibt

Lilium-Aktie im Rallymodus: Lilium wird übernommen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	29.12.2024 09:49
Kaufwert:	EUR
	Hinzufügen Speichern